Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study
Authors:
- Soo Jin ParkSPSoo Jin Park
- Jihye KimJKJihye Kim
- Hee Seung KimHKHee Seung Kim
- Jeong-Won LeeJLJeong-Won Lee
- Ha Kyun ChangHCHa Kyun Chang
- Keun Ho LeeKLKeun Ho Lee
- Dae-Yeon KimDKDae-Yeon Kim
- Sunghoon KimSunghoon Kim
- Suk-Joon ChangSCSuk-Joon Chang
- Seung Su HanSHSeung Su Han
- Sang-Yoon ParkSPSang-Yoon Park
- Seung-Hyuk ShimSSSeung-Hyuk Shim
Open Access
- 1 January 2020
- journal article
- research article
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 31 (2) , e15
Abstract
Park SJ, et al. J Gynecol Oncol. 2019 Jun;31:e15. https://doi.org/10.3802/jgo.2020.31.e15Keywords
Funding Information
- Konkuk University Medical Center
This publication has 32 references indexed in Scilit:
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerJournal of Clinical Oncology, 2012
- A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancerGynecologic Oncology, 2011
- Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trialAnnals of Oncology, 2011
- Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of ChemotherapyClinical Cancer Research, 2009
- Clinician versus nurse symptom reporting using the National Cancer Institute—Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaireAnnals of Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Phase II trial evaluating a docetaxel‐capecitabine combination as treatment for hormone‐refractory prostate cancerCancer, 2006
- Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)Annals of Oncology, 2005
- Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancerInternational Journal of Gynecological Cancer, 2005
- Pharmacokinetics of Pegylated Liposomal DoxorubicinClinical Pharmacokinetics, 2003